Who are DAS181-F02 Dry Powder in Bulk's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amevive, ETN Alone, Placebo matching with Abatacept, Enbrel (etanercept), Etanercept via Autoinjector A, abatacept (ABA).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/das181-f02-dry-powder-in-bulk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DAS181-F02 Dry Powder in Bulk — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DAS181-F02 Dry Powder in Bulk (DAS181-F02 Dry Powder in Bulk) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fusion protein. Area: Respiratory.

phase 2 Fusion protein Siglec-9 Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

DAS181-F02 Dry Powder in Bulk (DAS181-F02 Dry Powder in Bulk) — Ansun Biopharma, Inc.. DAS181-F02 Dry Powder in Bulk is a fusion protein that targets the sialic acid-binding immunoglobulin-like lectin 9 (Siglec-9) receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DAS181-F02 Dry Powder in Bulk TARGET	DAS181-F02 Dry Powder in Bulk	Ansun Biopharma, Inc.	phase 2	Fusion protein	Siglec-9
Amevive	ALEFACEPT	Astellas Pharma	marketed	CD2-directed LFA-3/Fc Fusion Protein	T-cell surface antigen CD2	2003-01-01
ETN Alone	ETN Alone	Japan Biological Agent Study Integrated Consortium	marketed	TNF-α inhibitor (TNF receptor fusion protein)	TNF-α (tumor necrosis factor-alpha)
Placebo matching with Abatacept	Placebo matching with Abatacept	Bristol-Myers Squibb	marketed	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Enbrel (etanercept)	Enbrel (etanercept)	Pfizer	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha)
Etanercept via Autoinjector A	Etanercept via Autoinjector A	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
abatacept (ABA)	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fusion protein class)

Ansun Biopharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DAS181-F02 Dry Powder in Bulk — Competitive Intelligence Brief. https://druglandscape.com/ci/das181-f02-dry-powder-in-bulk. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab